Publications by authors named "O Lukacova"

Alkaptonuria (AKU, OMIM, No. 203500) is a rare, slow-progressing, irreversible, multisystemic disease resulting from a deficiency of the homogentisate 1,2-dioxygenase enzyme, which leads to the accumulation of homogentisic acid (HGA) and subsequent deposition as pigment in connective tissues called ochronosis. As a result, severe arthropathy of large joints and spondyloarthropathy with frequent fractures, ligament ruptures, and osteoporosis develops in AKU patients.

View Article and Find Full Text PDF

Objectives: Ochronotic spondyloarthropathy represents one of the main clinical manifestations of alkaptonuria (AKU); however, prospective data and description of the effect of nitisinone treatment are lacking.

Methods: Patients with AKU aged 25 years or older were randomly assigned to receive either oral nitisinone 10 mg/day (N=69) or no treatment (N=69). Spine radiographs were recorded yearly at baseline, 12, 24, 36 and 48 months, and the images were scored for the presence of intervertebral space narrowing, soft tissue calcifications, vacuum phenomena, osteophytes/hyperostosis and spinal fusion in the cervical, thoracic and lumbosacral segment at each of the time points.

View Article and Find Full Text PDF

Background: Alkaptonuria is a rare, genetic, multisystem disease characterised by the accumulation of homogentisic acid (HGA). No HGA-lowering therapy has been approved to date. The aim of SONIA 2 was to investigate the efficacy and safety of once-daily nitisinone for reducing HGA excretion in patients with alkaptonuria and to evaluate whether nitisinone has a clinical benefit.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to gather insights and expert opinions on using TNF-α antagonists to treat patients with systemic sclerosis (SSc).
  • Researchers collected data from EUSTAR centers regarding the frequency and outcomes of TNF-α antagonist treatments, followed by a Delphi exercise to reach a consensus among experts.
  • Results showed that while 71% of experts initially supported the use of TNF-α antagonists for SSc, acceptance dropped to 41% after further discussion, indicating a strong need for clinical trials before routine recommendations can be made.
View Article and Find Full Text PDF

Systemic lupus erythematodes (SLE) is chronic autoimmune disease, characteristic by production of autoantibodies against different autoantigens. Etiopathogenesis in not precise determinated, but genetic, immunologic, hormonal factors or influence of environment are assumed. It manifests by various symptoms and it can affect whichever organ or system in the body.

View Article and Find Full Text PDF